[{"orgOrder":0,"company":"Sarborg","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Sarborg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sarborg \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Sarborg \/ Conduit Pharma"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Conduit Pharma \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"ClinConnect","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"ClinConnect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ClinConnect \/ Conduit Pharma","highestDevelopmentStatusID":"8","companyTruncated":"ClinConnect \/ Conduit Pharma"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Conduit Pharma \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Conduit Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Conduit Pharma","sponsor":"Sarborg Limited","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase II","graph3":"Conduit Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Conduit Pharma \/ Sarborg Limited","highestDevelopmentStatusID":"8","companyTruncated":"Conduit Pharma \/ Sarborg Limited"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Conduit Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AZD1656","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Conduit Pharma","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Conduit Pharma"}]